News >

Dostarlimab Demonstrates Efficacy in Endometrial Cancer

Brandon Scalea
Published: Thursday, May 23, 2019

Ana Oaknin, MD, PhD

Ana Oaknin, MD

An investigational anti–PD-1 therapy led to durable responses across microsatellite instability–high (MSI-H) and microsatellite stable (MSS) subgroups of patients with advanced or recurrent endometrial cancer, a population with a historically poor prognosis, said Ana Oaknin, MD.

Results from the phase I/II GARNET study showed that treatment with dostarlimab (TSR-042) led to an overall response rate (ORR) of 29.6% in the general patient population. In the subgroup of patients with MSI-H tumors, the ORR was even higher at 48.8%; in those whose tumors were MSS, it was 20.3%. Furthermore, the disease control rate was 52.8% in the entire study population, 63.4% in those with MSI-H tumors, and 46.8% in patients with MSS tumors.

The median duration of response with the antibody was not reached at a median follow-up of 10 months. Of the overall population, 89% of patients remained on treatment for >6 months, while 49% continued for >1 year.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x